Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02373384
Other study ID # AEl-Sawy122015
Secondary ID
Status Completed
Phase Phase 4
First received February 13, 2015
Last updated March 21, 2018
Start date February 2015
Est. completion date June 2017

Study information

Verified date March 2018
Source Mansoura University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the study is to evaluate the predictors of success of oral dissolution therapy in radiolucent renal stones in a large series of patients from a tertiary referral center in order to define the optimum case scenarios where oral dissolution therapy could be implemented.


Description:

Patients with renal stones, seen through the outpatient clinic in the urology department or post primary intervention for renal stones, will be assessed to see if the patient satisfies all inclusion and exclusion criteria. Patients who are meeting these criteria will be asked to participate in this prospective study. If they agree, they will be asked to sign an informed consent.

Baseline patients` assessment will include;

- Full history taking including

- Previous stone history regarding presentation and management

- Previous trial oral dissolution therapy for renal stones and their compliance to the treatment

- Previous GIT surgery

- History of chronic medical or metabolic illness e.g; DM

- Clinical examination including

o Body mass index (BMI)

- Laboratory investigations including;

- Urine analysis (urine PH)

- 24 hours urine testing for uric acid and citrate

- Urine culture

- Serum creatinine

- Random blood sugar (RBS)

- Serum uric acid

- Serum calcium, phosphorus and magnesium.

- Initial radiological evaluation will include

- Renal ultrasonography (US)

- Plain X-rays to exclude the presence of calcification in the targeted stone.

- Non Contrast Computed Tomography (NCCT) on the abdomen and pelvis.

- MAG3 diuretic renogram

(All NCCT studies will be performed with multislice helical CT scanners, NCCT images will be obtained from above the kidneys through the bladder base. For each renal stone, its location will be recorded, its size will be measured using the largest dimension from length (L), width (W) and height (H) on axial and coronal reformat images. Its mean density will be recorded by measurement using region of interest just smaller than the stone. Associated hydronephrosis proximal to the stone will be also evaluated (Nakada et al 2000).)

Patient will receive the allocated instructions and medications

Patients` follow up (The aim at follow up is to monitor the urinary PH with adjustment of the dose of potassium citrate and also to assess the compliance of the patients regarding the dietary recommendations and the medications)

- After 2 weeks, 4 weeks, 8 weeks and 12 weeks.

- the most important parameter will be assessed is the urinary PH every two weeks. The target urinary PH should be kept between6.5 to 7.0, the dose of potassium citrate should be adjusted to achieve this value.

- Patients` compliance to medications intake and the instruction of fluid intake and dietary modification.


Recruitment information / eligibility

Status Completed
Enrollment 182
Est. completion date June 2017
Est. primary completion date February 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients' criteria:

1. Ability to give informed consent.

2. Age more than 18 years.

3. Absence of significant hydronephrosis, serious urinary tract infection, congenital anomalies or distal ureteric obstruction in the affected renal unit.

4. Normal cardiac, hematological, and renal functions.

- Stone criteria:

1. Primary or recurrent renal stone.

2. Patients with residual renal stones after primary intervention whether open surgery, endoscopic or ESWL.

3. Peripheral calyceal stones or stone in the renal pelvis with no significant hydronephrosis.

4. Stone size less than 3 cm in maximum diameter

5. Stones with radiodensity less than 600 Hounsefield units attenuation in Non Contrast Computed Tomography (NCCT).

Exclusion Criteria:

- Patients' criteria:

1. Inability to give informed consent.

2. Age less than 18 years

3. Patients with unremitting pain or serious urinary tract infection.

4. Presence of significant hydronephrosis, congenital anomalies or distal ureteric obstruction in the affected renal unit.

5. Abnormal cardiac, hematological or renal functions.

- Stone criteria:

1. Obstructing stone in the renal pelvis with significant hydronephrosis.

2. Assumption of presence of calcium stones by presence of calcification in the stone in plain X-rays.

Study Design


Intervention

Drug:
Oral alkalinization (Potassium citrate, Allopurinol)
Eligible patients, who fulfilled the study criteria, will be instructed For; Oral alkalinization therapy Potassium citrate 20 mEq three times daily Hyperuricosuric patients (24-hours urine uric acid more than 750 mg/day in male and more than 650mg/day in females) will receive: Allopurinol, a competitive inhibitor of xanthine oxidase, in a dose of 300 mg daily.
Behavioral:
Life style modification
Eligible patients, who fulfilled the study criteria, will be also instructed for; Adequate fluid intake in order to maintain urine volume between 2-3 L per day.
Dietary Supplement:
Dietary recommendations (decrease purine rich diet as red meat and fish, increase vegetables)
Eligible patients, who fulfilled the study criteria and they are hyperuricosuric (24-hours urine uric acid more than 750 mg/day in male and more than 650mg/day in females) will be also instructed for; Dietary modification will be advised in the form of decrease purine rich diet as red meat and fish, increase vegetables.

Locations

Country Name City State
Egypt Urology and Nephrology Center Mansoura DK

Sponsors (1)

Lead Sponsor Collaborator
Mansoura University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Other The cost efficiency of this procedure Cumulative cost of medical treatment, including cost of medications and cost savings of sparred medical resources of interventional treatment will be assessed. participants will be followed for the duration of medical treatment which is specified to be 3 months
Primary The primary endpoint of this study will be change in stone surface area after 3 months of the determined protocol The stone surface area will be measured using the formula; Surface area = length X width X 0.25 X (22/7) Comparison of the stone surface area in relation to the initial surface area will be done. participants will be followed for the duration of medical treatment which is specified to be 3 months
Secondary Assessment of the predictors of response (more than 50% reduction in the surface area of the stone) to medical treatment The percent reduction of stone surface area will be calculated using the formula:
Surface area = length X width X 0.25 X (22/7)
Categorization of the patients into three groups will be done:
Patients who achieved 50% or more reduction in the stone surface area will be considered responsive and would be counseled for another 3 months therapy.
Patients with partial response, less than 50% reduction in stone surface area will be counseled for auxiliary procedure based on stone criteria e.g. ESWL.
Patients with no response/ serious renal infections or serious treatment adverse effects will be considered for other interventional treatment modalities.
In the responders groups, factors predicting the success of treatment will be determined
participants will be followed for the duration of medical treatment which is specified to be 3 months
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04746378 - PRedictive Accuracy of Initial Stone Burden Evaluation.
Recruiting NCT05100017 - Methocarbamol vs Oxybutynin for Management of Pain and Discomfort S/P Ureteroscopy Procedure N/A
Recruiting NCT04021381 - Citrate Salts for Stone-free Result After Flexible Ureterorenoscopy for Inferior Calyx Calculi Phase 3
Completed NCT02266381 - A Prospective Comparison of Fluoroscopic, Sonographic or Combined Approach for Renal Access in Percutaneous Nephrolithotomy N/A
Completed NCT01451931 - Study of Tomography of Nephrolithiasis Evaluation Phase 4
Terminated NCT01431378 - Pilot Study of Model Based Iterative Reconstruction Using 64-Slice N/A
Completed NCT01295879 - Vitamin D Repletion in Stone Formers With Hypercalciuria Phase 4
Completed NCT02895711 - Radiation Dose of Pediatric Patients During Ureteroscopy
Completed NCT05340075 - Staged Bilateral Percutaneous Nephrolithotomy
Recruiting NCT03919227 - Measurement of Resistance During UAS Insertion Procedure in RIRS N/A
Recruiting NCT03717285 - Under Direct Vision vs Under Non Direct Vision of Insertion of UAS in RIRS N/A
Completed NCT05340088 - Optimal Passive Dilation Time in Retrograde Intrarenal Surgery
Completed NCT05032287 - Medical Expulsive Therapy Post-SWL For Renal Stones N/A
Recruiting NCT05701098 - SOUND Pivotal Trial - (Sonomotion stOne comminUtion resoNance ultrasounD) N/A
Not yet recruiting NCT04080973 - Metabolic Workup in Patients Suffering From Kidney Stone Disease and Osteopenia N/A
Terminated NCT01736358 - The Use of Intranasal Ketoralac for Pain Management (Sprix) Phase 4
Completed NCT01792765 - Management of Ureteral Calculi Using Ultrasound Guidance: A Radiation Free Approach N/A
Completed NCT06211842 - Genetic Variations That Increase the Risk for Calcium Kidney Stones: a Family-based Study
Not yet recruiting NCT02214836 - Ultrasound Imaging of Kidney Stones and Lithotripsy N/A
Not yet recruiting NCT04606758 - Fluoroscopic Guided vs US-guided Percutaneous Nephrolithotripsy for the Treatment of Stone Disease N/A